In summarizing this section, various pharmacodynamic and proof-of-mechanism biomarkers have been developed which can be utilised to measure inhibition of the PI3K pathway in tumour biopsies and surrogate normal tissues. The gene discussed is PIK3CD; the disease is neoplasm.